4-chloro-N-[(2S)-1-[4-(2-fluoroethyl)piperidin-1-yl]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]pyridine-3-sulfonamide | 231289-96-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-chloro-N-[(2S)-1-[4-(2-fluoroethyl)piperidin-1-yl]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]pyridine-3-sulfonamide
• CAS: 231289-96-6
• 化学式: C₂₂H₂₇ClFN₃O₄S
• 分子量: 483.991
• InChiKey: KDZUMHRTKHPPMF-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  97
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  L-苯丙氨醇 、 4-chloro-N-[(2S)-1-[4-(2-fluoroethyl)piperidin-1-yl]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]pyridine-3-sulfonamide 以 乙醇 为溶剂， 以96%的产率得到N-[(2S)-1-[4-(2-fluoroethyl)piperidin-1-yl]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-4-[[(2S)-1-hydroxy-3-phenylpropan-2-yl]amino]pyridine-3-sulfonamide
  参考文献：
  名称：

  The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore

  摘要：

  Thrombin inhibitors have been designed with the replacement of the strongly basic guanidine P1 pharmocophore with a group that exploits the lipophilicty of the S1 pocket. The approach has lead to the discovery of potent thrombin inhibitors demonstrating good intra-duodenal absorption. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00138-9
• 作为产物：
  描述：

  4-羟基吡啶-3-磺酸 在 五氯化磷 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 生成 4-chloro-N-[(2S)-1-[4-(2-fluoroethyl)piperidin-1-yl]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]pyridine-3-sulfonamide
  参考文献：
  名称：

  The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore

  摘要：

  Thrombin inhibitors have been designed with the replacement of the strongly basic guanidine P1 pharmocophore with a group that exploits the lipophilicty of the S1 pocket. The approach has lead to the discovery of potent thrombin inhibitors demonstrating good intra-duodenal absorption. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00138-9

文献信息

• Anticoagulant contrast media
  申请人：Melton J. Laura

  公开号：US20050281746A1

  公开（公告）日：2005-12-22

  The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.

  本发明提供了一种新型抗凝对比剂，包括有机支架基团、有机抗凝基团和成像基团。该发明还提供了抗凝对比介质和利用新型抗凝对比剂和抗凝对比介质来可视化内部结构的方法。
• The Discovery of orally available thrombin inhibitors : Studies towards the optimisation of CGH1668
  作者：John Ambler、Emma Baker、Lyndon Brown、Paul Butler、Dave Farr、Karen Dunnet、Darren Le Grand、Diana Janus、Darryl Jones、Keith Menear、Mark Mercer、Garrick Smith、Mark Talbot、Morris Tweed

  DOI：10.1016/s0960-894x(98)00640-4

  日期：1998.12

  The chemical optimisation of CGH1668 1 is described employing an in vivo model of absorption to determine the influence on bioavailability of single Feint modifications to five key molecular templates. The discovery of an orally bioavailable and selective thrombin inhibitor, 24, highlights the utility of this approach. (C) 1998 Elsevier Science Ltd. All rights reserved.
• The discovery of orally available thrombin inhibitors: Optimisation of the P1 pharmacophore
  作者：John Ambler、David Bentley、Lyndon Brown、Karen Dunnet、Dave Farr、Diana Janus、Darren Le Grand、Keith Menear、Mark Mercer、Mark Talbot、Morris Tweed、Bernard Wathey

  DOI：10.1016/s0960-894x(99)00138-9

  日期：1999.4

  Thrombin inhibitors have been designed with the replacement of the strongly basic guanidine P1 pharmocophore with a group that exploits the lipophilicty of the S1 pocket. The approach has lead to the discovery of potent thrombin inhibitors demonstrating good intra-duodenal absorption. (C) 1999 Elsevier Science Ltd. All rights reserved.